Get the Stockscreener App
15.19
2.50%
0.37
After Hours:
15.19
Amneal Pharmaceuticals Inc stock is traded at $15.19, with a volume of 2.56M.
It is up +2.50% in the last 24 hours and up +13.27% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$14.82
Open:
$14.9
24h Volume:
2.56M
Relative Volume:
1.10
Market Cap:
$4.78B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-22.32
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+2.91%
1M Performance:
+13.27%
6M Performance:
+60.74%
1Y Performance:
+96.51%
1-Day Range:
$14.85
$15.42
1-Week Range:
$14.55
$15.42
52-Week Range:
$6.685
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
15.19 | 4.66B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.26 | 58.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.56 | 53.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.23 | 49.87B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.41 | 39.57B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
482.42 | 20.39B | 3.13B | 1.27B | 1.12B | 26.39 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 52-Week HighShould You Buy? - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at 15.08 USD - Investing.com
7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds - Insider Monkey
Is Amneal Pharmaceuticals Inc. a potential multi bagger2025 Winners & Losers & AI Powered Trade Plan Recommendations - mfd.ru
Travel Stocks: Is Amneal Pharmaceuticals Inc a strong candidate for buy and holdLayoff News & Smart Money Movement Alerts - baoquankhu1.vn
Is Amneal Pharmaceuticals Inc. stock undervalued right nowWeekly Risk Summary & Smart Allocation Stock Tips - mfd.ru
Is Amneal Pharmaceuticals Inc. forming a double bottomJuly 2025 Snapshot & Capital Efficient Trade Techniques - mfd.ru
Resistance Check: How does Amneal Pharmaceuticals Inc perform in inflationary periodsPortfolio Value Summary & Smart Money Movement Tracker - baoquankhu1.vn
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market - Benzinga
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Up 87.3% in January - MarketBeat
What makes Amneal Pharmaceuticals Inc. stock attractive todayOptions Play & AI Forecasted Stock Moves - mfd.ru
What Amneal Pharmaceuticals (AMRX)'s Addition to the S&P 1000 Index Means For Shareholders - Yahoo Finance
Options Flow: Can Amneal Pharmaceuticals Inc continue delivering strong returns2025 Technical Patterns & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Is Amneal Pharmaceuticals Inc. in a long term uptrend2025 Momentum Check & Long-Term Growth Portfolio Plans - mfd.ru
Doseology Sciences Launches New Energy Product Line - Intellectia AI
What Amneal Pharmaceuticals (AMRX)'s Index Additions and Opioid Settlement Mean For Shareholders - simplywall.st
Earnings Report: Will Amneal Pharmaceuticals Inc benefit from current market trendsWeekly Risk Report & Verified Momentum Watchlists - baoquankhu1.vn
What are the future prospects of Amneal Pharmaceuticals IncJuly 2025 News Drivers & Fast Gain Stock Tips - baoquankhu1.vn
Amneal Receives FDA Approval for Sodium Oxybate Oral Solution - Sleep Review
Breakouts Watch: What’s the outlook for SPAR Group Inc.’s sectorTrade Analysis Summary & High Win Rate Trade Alerts - baoquankhu1.vn
Is Amneal Pharmaceuticals (AMRX) a great value stock right now? - MSN
Is Amneal Pharmaceuticals (AMRX) a Great Value Stock Right Now? - Yahoo Finance
Guidance Update: Is Amneal Pharmaceuticals Inc a strong candidate for buy and holdTrade Analysis Summary & Low Risk Entry Point Guides - baoquankhu1.vn
Amneal Pharmaceuticals Refinances Term Loans, Lowers Interest Costs - TipRanks
Amneal Pharma Says On Feb 2nd, Co Enters Amendment No. 2 To Term Loan Credit AgreementSEC Filing - TradingView
Amneal Pharmaceuticals Signs Term Loan Credit Agreement Amendment With JPMorgan Chase - TradingView
How Investors Are Reacting To Amneal Pharmaceuticals (AMRX) Index Additions And Opioid Settlement Resolution - Sahm
Will Amneal (AMRX) beat estimates again in its next earnings report? - MSN
Amneal initiates nationwide settlement for opioid-related claims - MSN
Aug Sentiment: Is Amneal Pharmaceuticals Inc stock a hidden gem2025 Pullback Review & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Risk Check: Does Ormat Technologies Inc stock benefit from AI growth2025 Market Outlook & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
AustralianSuper Pty Ltd Makes New Investment in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi‑Year Share Price Run? - Yahoo Finance
Opioid Settlement And Index Inclusion Reframe Amneal Pharmaceuticals Risk And Reach - Yahoo Finance
If You Invested $100 In Amneal Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today - Sahm
Published on: 2026-01-30 06:37:48 - baoquankhu1.vn
Amneal initiates nationwide opioid settlement (AMRX:NASDAQ) - Seeking Alpha
Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi Year Run? - Sahm
Amneal Finalizes Nationwide Opioid Settlement Implementation Plan - TipRanks
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index - The Manila Times
Amneal Pharma To Settle Majority Of Opioids-Related Claims - TradingView
Amneal Pharmaceuticals Finalizes Nationwide Opioids Settlement - TradingView
Amneal Pharmaceuticals, Inc. Added to S&P SmallCap 600® Index - Quiver Quantitative
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
Amneal Pharmaceuticals (NASDAQ:AMRX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Amneal Pharmaceuticals, Inc. $AMRX Shares Sold by SG Americas Securities LLC - MarketBeat
TTM Technologies, Dutch Bros to join S&P 400 Index; Amneal, Apellis to be part of S&P SmallCap 600 (CIVI:NYSE) - Seeking Alpha
Amneal, LegalZoom, others rise as S&P Dow Jones Indices announces index changes - Investing.com Canada
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 1-Year HighStill a Buy? - MarketBeat
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 - The Manila Times
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):